INOVIQ Exosome Platform Validated for Parkinson’s Disease EV Isolation
Posted: 22 August 2024 INOVIQ Limited (ASX:IIQ or INOVIQ) is pleased to announce that it has further validated its NEURONET™ technology for isolation of brain-derived exosomes in Parkinson’s Disease (PD). On June 24th this year, INOVIQ reported that…
Noxopharm Targets Clinical Trial for First-in-Class Drug
Posted: 19 August 2024 Innovative biotech company Noxopharm Limited (ASX:NOX) is pleased to announce its first in-human trial for SOF-SKN™, a novel drug candidate for autoimmune diseases. The trial is planned to start in early calendar year 2025…
Global launch of geneType™ on wholly owned EasyDNA platform
Posted: 19 August 2024 Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a global leader in genomics-based tests in health, wellness and serious disease and the parent company of geneType™, is pleased to announce the global launch…
ANDHealth & TGA extend partnership
Posted: 19 August 2024 A joint initiative between ANDHealth and the Therapeutic Goods Administration (TGA) will continue providing regulation and registration support for digital medical software companies looking to commercialise new products that can help improve health outcomes…
Australian Medical Device Essential Principles – Part 2: Proposed alignment with the European Regulation
Posted: 19 August 2024 Closes: 16 October 2024 Overview The Therapeutic Goods Administration (TGA) is the Australian government authority responsible for the regulation of therapeutic goods including medicines, medical devices, and biologicals. The Australian (AUS) Essential Principles set…
Immutep Announces First Participant Dosed in Phase I Study of IMP761, a First in Class Agonist LAG-3 Antibody
Posted: 14 August 2024 Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces that the first participant has been successfully dosed in…
AusBiotech selected as Industry Partner Organisation for Australia’s Industry Growth Program
Posted: 14 August 2024 AusBiotech, Australia’s leading life science organisation, has been announced as an Industry Partner Organisation (IPO) under the Australian Government’s Industry Growth Program (IGP). AusBiotech welcomed its selection as an Industry Partner Organisation to provide…
Breakthrough Victoria CEO steps down
Posted: 14 August 2024 Breakthrough Victoria’s inaugural CEO, Grant Dooley, today announced he is stepping down after three successful years building and leading the Victorian Government’s technology innovation and commercialisation fund. Dooley will stay on to support BV’s…
IDT Secures New Contract with Sanofi Australia
Posted: 14 August 2024 IDT Australia Limited (ASX: IDT) (IDT or the Company) is pleased to announce that it has secured a follow-on contract with Sanofi Australia (Sanofi) worth between $2.5 million and $4 million for the preclinical…
Phase 2 trial shows significant improvements in Angelman syndrome
Posted: 14 August 2024 Neuren Pharmaceuticals (ASX: NEU) today announced top-line results from its Phase 2 clinical trial of NNZ-2591 in children with Angelman syndrome (AS). NNZ-2591 was safe and well tolerated as an oral liquid dose and…
Pfizer upgrades its plant in Melbourne to become one of the most advanced pharmaceutical production facilities in Australia
Posted: 13 August 2024 Australia is stepping up to the global fight against antimicrobial resistance, as Pfizer Australia announces a major upgrade to its manufacturing facility in Melbourne, Victoria. Pfizer has invested AU$150 million to offer advanced pharmaceutical…
Pfizer calls for action to attract global life sciences investment in Australia
Posted: 13 August 2024 Pfizer Australia is urging policy change to make Australia more attractive for global life sciences investment. In its new report, ‘Breakthrough Nation’, launched at the beginning of National Science Week (10-18 August), Pfizer highlights…
